BeiGene Current Ratio 2014-2024 | ONC
Current and historical current ratio for BeiGene (ONC) from 2014 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. BeiGene current ratio for the three months ending September 30, 2024 was 1.93.
| BeiGene Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$3.91B |
$2.03B |
1.93 |
| 2024-06-30 |
$3.84B |
$1.94B |
1.98 |
| 2024-03-31 |
$3.91B |
$1.88B |
2.08 |
| 2023-12-31 |
$4.20B |
$1.81B |
2.32 |
| 2023-09-30 |
$4.05B |
$1.28B |
3.16 |
| 2023-06-30 |
$4.40B |
$1.41B |
3.13 |
| 2023-03-31 |
$4.70B |
$1.26B |
3.75 |
| 2022-12-31 |
$5.21B |
$1.47B |
3.55 |
| 2022-09-30 |
$5.75B |
$1.41B |
4.07 |
| 2022-06-30 |
$6.35B |
$1.40B |
4.54 |
| 2022-03-31 |
$6.95B |
$1.38B |
5.05 |
| 2021-12-31 |
$7.61B |
$1.60B |
4.76 |
| 2021-09-30 |
$4.43B |
$1.30B |
3.40 |
| 2021-06-30 |
$4.80B |
$1.24B |
3.86 |
| 2021-03-31 |
$5.14B |
$1.11B |
4.62 |
| 2020-12-31 |
$4.96B |
$1.08B |
4.61 |
| 2020-09-30 |
$4.97B |
$0.65B |
7.69 |
| 2020-06-30 |
$3.39B |
$0.55B |
6.16 |
| 2020-03-31 |
$3.60B |
$0.45B |
7.96 |
| 2019-12-31 |
$1.17B |
$0.31B |
3.78 |
| 2019-09-30 |
$1.44B |
$0.27B |
5.40 |
| 2019-06-30 |
$1.76B |
$0.27B |
6.46 |
| 2019-03-31 |
$1.80B |
$0.24B |
7.52 |
| 2018-12-31 |
$1.94B |
$0.25B |
7.89 |
| 2018-09-30 |
$2.18B |
$0.19B |
11.57 |
| 2018-06-30 |
$1.52B |
$0.19B |
8.14 |
| 2018-03-31 |
$1.59B |
$0.14B |
11.18 |
| 2017-12-31 |
$0.91B |
$0.15B |
6.09 |
| 2017-09-30 |
$0.96B |
$0.10B |
9.33 |
| 2017-06-30 |
$0.42B |
$0.05B |
8.38 |
| 2017-03-31 |
$0.34B |
$0.05B |
6.73 |
| 2016-12-31 |
$0.37B |
$0.04B |
10.68 |
| 2016-09-30 |
$0.21B |
$0.03B |
7.16 |
| 2016-06-30 |
$0.23B |
$0.02B |
11.37 |
| 2016-03-31 |
$0.25B |
$0.02B |
15.91 |
| 2015-12-31 |
$0.11B |
$0.04B |
3.02 |
| 2015-09-30 |
$0.13B |
$0.03B |
4.53 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.05B |
$0.01B |
3.53 |
| 2013-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
